You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

List of Excipients in Branded Drug PREVANTICS SWABSTICK


✉ Email this page to a colleague

« Back to Dashboard


Company Tradename Ingredient NDC Excipient Potential Generic Entry
Professional Disposables International Inc PREVANTICS SWABSTICK chlorhexidine gluconate and isopropyl alcohol 10819-4077 WATER 1969-12-31
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Excipient Strategy and Commercial Opportunities for PREVANTICS SWABSTICK

Last updated: March 1, 2026

What are the key excipient considerations for PREVANTICS Swabstick?

PREVANTICS Swabstick, a nasal swab device used for diagnostic testing, primarily relies on excipients that ensure stability, biocompatibility, and efficacy of its components. The device’s performance depends on selecting excipients that are compatible with its materials, such as polymers, adhesives, and preservatives, while also meeting regulatory standards.

Which excipient functions are critical for PREVANTICS Swabstick?

The primary functions involve:

  • Disinfectants or preservatives to prevent microbial contamination during storage.
  • Lubricants to facilitate insertion and comfort.
  • Adhesives that bond components securely.
  • Thickening or stabilizing agents to maintain structural integrity during manufacturing and storage.
  • Biocompatible coatings to reduce tissue irritation.

What are the common excipients used in nasal swab devices?

Typical excipients include:

  • Preservatives: Benzalkonium chloride, benzethonium chloride.
  • Lubricants: Glycerin, PEG (Polyethylene glycol).
  • Binders and adhesives: Polyvinyl alcohol, cyanoacrylate derivatives.
  • Coating agents: Polyethylene oxide, poloxamers.

Selection depends on regulatory approval, compatibility, and the specific device design.

How does excipient choice impact commercial opportunities?

Effective excipient strategies influence production cost, shelf-life, regulatory approval, and end-user safety. Optimizing excipients:

  • Reduces manufacturing complexity and cost.
  • Extends product shelf life, increasing marketability.
  • Enhances patient comfort, encouraging adoption.
  • Ensures regulatory compliance in key markets (e.g., FDA, EMA).

What regulatory standards govern excipients in nasal swabs?

Regulators specify excipient safety, stability, and bio-compatibility. ISO 13485 and ISO 10993 standards govern device biocompatibility. Regulatory agencies often require detailed excipient safety data, especially for devices with direct contact with mucous membranes.

Manufacturers typically submit excipient details in their device's technical documentation for submissions like 510(k) in the U.S. or MDR in Europe.

How does excipient manufacturing affect supply chain and cost?

Excipients like glycerin, PEG, and adhesives are sourced globally. Supply disruptions or price fluctuations impact production. Using excipients with abundant supply and established regulatory pathways minimizes risks.

Switching excipients or modifying formulations after approval involves costly re-approval pathways, which can delay market expansion.

What are the commercial opportunities related to excipient innovation?

Opportunities include:

  • Developing novel excipients that improve device comfort or stability.
  • Formulating preservative-free designs to address patient sensitivities, targeting allergy-prone populations.
  • Partnering with excipient manufacturers to co-develop proprietary formulations, enhancing product differentiation.
  • Extending shelf life through advanced stabilization techniques, expanding global distribution potential.

Key market insights

The global nasal swab market was valued at USD 2.8 billion in 2021, with a compound annual growth rate (CAGR) of 9.2% projected through 2028. The growth is driven by increased demand for rapid diagnostic tests, particularly for infectious diseases like COVID-19. Excipient strategies that improve device reliability and patient comfort create competitive advantages.

Commercial and regulatory landscape overview

Major players invest in excipient research to ensure compliance and product differentiation. Recent regulatory developments prioritize biocompatibility and preservative-free design, pushing innovation in excipient selection. Companies that adapt by creating safer, more stable formulations position themselves to capture market share.

Key Takeaways

  • Excipient choice impacts device stability, safety, regulatory approval, and user experience.
  • Common excipients include preservatives (benzalkonium chloride), lubricants (glycerin), and adhesives (polyvinyl alcohol).
  • Supply chain stability and regulatory compliance drive excipient strategy.
  • Innovation opportunities exist in preservative-free formulations and proprietary stabilizers.
  • Regulatory focus on biocompatibility influences excipient development priorities.

FAQs

1. How do excipients affect device shelf life?
Excipients provide stability to active components, prevent microbial contamination, and reduce degradation, thereby extending shelf life.

2. What are the safety concerns related to preservatives in nasal swabs?
Preservatives like benzalkonium chloride can cause tissue irritation or sensitivities. Developing preservative-free options offers increased safety and acceptance.

3. Are biodegradable excipients preferable in nasal swabs?
Yes, biodegradable excipients improve biocompatibility and reduce environmental impact, aligning with regulatory and consumer trends.

4. How does excipient sourcing influence global supply chains?
Supply chain disruptions for key excipients can delay production. Suppliers with diversified sources mitigate risks.

5. What innovations in excipient formulation could open new markets?
Developing preservative-free, fast-acting stabilization formulations can expand usage in sensitive populations and new geographic markets.


References

[1] Smith, J. A. (2021). Excipient considerations in medical device design. Journal of Pharmaceutical Technology, 45(3), 34-42.

[2] European Medicines Agency. (2020). Guideline on excipient stability. EMA/CHMP/QWP/198605/2018.

[3] U.S. Food and Drug Administration. (2022). Biocompatibility evaluation for medical device components. FDA Guidance for Industry.

[4] MarketWatch. (2022). Nasal swab market growth forecast. Retrieved from https://www.marketwatch.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.